VisiCELL Medical
Private Company
Funding information not available
Overview
VisiCELL Medical is a private, pre-revenue biotech tools company founded in 2015 and based in San Diego. It has developed a proprietary nanomaterial-based imaging platform that uses standard MRI to non-invasively track the location and persistence of therapeutic cells (e.g., CAR-T, NK, stem cells) in the body. The company's value proposition is to de-risk and accelerate cell therapy development by providing critical biodistribution and efficacy data, serving as an enabling service/platform for therapy developers. Its leadership combines expertise in nanomaterials, radiology, and business, with technology originating from foundational research published in Nature Medicine.
Technology Platform
Proprietary nanomaterial-based cell labeling for non-invasive, in vivo tracking of therapeutic cells (e.g., CAR-T, NK, stem cells) using standard clinical MRI scanners. Enables longitudinal biodistribution and persistence data from preclinical to clinical stages.
Opportunities
Risk Factors
Competitive Landscape
VisiCELL competes with other cell tracking methods, including PCR-based assays, bioluminescence imaging (preclinical), and PET imaging (often using radioactive labels). Its key differentiator is the use of non-radioactive, clinically ubiquitous MRI. Other MRI-based tracking technologies may exist in academia or at early-stage competitors, but VisiCELL's focus on a packaged, clinically applicable platform is a distinct positioning.